4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating […]
